CILcare, a preclinical provider in otology, will hold a free webinar on July 9 at 8 pm (CEST) called “How to Assess Drug Candidates on Tinnitus Preclinical Models For a Successful Transition to Clinical Trials.”
A new webinar featuring Drs Douglas Beck and Clifford Olson addresses how Covid-19 is changing hearing healthcare private practice and the hearing industry. The webinar, recorded on Friday, June 19, 2020, is now available on demand.
Auris Medical will develop betahistine dihydrochloride in a spray formulation for the intranasal treatment of Ménière’s disease and vestibular vertigo. The company also announced last week that it has resumed patient enrollment in the TACTT3 Phase 3 trial of Keyzilen® (AM-101) for acute and post-acute inner ear tinnitus.
Hearing healthcare practices made good progress toward recovery in May and look to do significantly better in June, according to results from The Hearing Review’s third survey that looks at the impact of the coronavirus on our field.
Approximately two-thirds of patients in this study (66.1%) self-reported visio-vestibular problems. Overall, 74.3% of patients had a visio-vestibular assessment at some point in their care and among these patients, 62.7% had identifiable deficits.